What is COVI-001?

COVI-001 is a combination of two FDA approved medications that is a revolutionary advance for patients with severe symptoms who are admitted to the hospital and need oxygen or are intubated. There is no treatment in the world like COVI-001.

The COVID-19 infection has two stages. The first stage is viral replication for which many drugs have been shown to provide benefit. Most people survive the first stage without serious incident. A small percentage go on to the second stage which is characterized by an overactive immune response referred to as a cytokine storm that often leads to death. There is no therapeutic available which is widely accepted to be effective that treats COVID-19 after the inflammatory phase of the disease takes hold other than dexamethasone, which provides mild benefit. Enter COVI-001.

With COVI-001, Covinnovations™ has identified a drug that appears to terminate the cytokine storm by suppressing IL-6 activity. A retrospective study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01) in patients hospitalized with COVID-related hypoxia when compared to standard of care. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%.

Covinnovations™ is proceeding with FDA approval to fast track COVI-001 for Emergency Use Authorization (EUA). Once approved, COVI-001 will become the standard treatment for all hospitalized COVID-19 patients in the U.S. who require oxygen support. As a result, COVI-001 will become the standard of care around the world. This advance in treatment will equate to millions and millions of doses of COVI-001 administered worldwide. Our research indicates that there is no other late-stage treatment like COVI-001. We are receiving funding to complete the FDA Emergency Use Authorization (EUA) fast track process which will then allow for full-scale production and distribution of this revolutionary treatment. Our clinical scientists have established trial protocols that are ready to deploy around the world.

What is COVI-101?

Our COVI-101 Rapid RNA Test is a non-invasive saliva/swab test and will produce a positive or a negative result in 2 minutes. This test can be performed at airports, schools, work establishments, sporting events, concerts, or in the comfort of your own home. Results this accurate and fast will remove many restrictions for current events. Most importantly, COVI-101 will provide the safest environment possible for all. CovInnovations has opened negotiations with a contract research organization operated by Johnson & Johnson.